What it is
DSIP is a nine-amino-acid peptide identified in chemical databases as emideltide. PubChem lists the sequence as WAGGDASGE; an identity record does not establish that a catalog preparation matches that sequence.
Mechanism and research questions
- Historical research examined slow-wave sleep, circadian patterns, neuroendocrine signals, and neurotransmitter-related effects.
- The biological mechanism and the relationship between DSIP-like immunoreactivity and a defined endogenous peptide remain unresolved in later review literature.
Human evidence
Older controlled studies in small groups of adults examined sleep-related endpoints. One study concluded that short-term treatment was unlikely to provide major therapeutic benefit; these studies do not establish modern clinical efficacy or safety for research-vial material.
Preclinical / mechanistic evidence
Rat studies examined slow-wave sleep and sleep-related growth-hormone release, and later animal work investigated phosphorylated DSIP or DSIP-like analogues. Findings from animals or modified analogues should not be attributed directly to unmodified DSIP in humans.
Evidence summary
Small, older human sleep studies reported mixed or weak findings, while animal studies provide additional mechanistic context. This evidence is not a basis for treatment or outcome claims.
Limits and interpretation
- The directly located human literature is small, old, and context-specific.
- Evidence for DSIP itself must be separated from evidence for phosphorylated or DSIP-like analogues.
- The mechanism, endogenous biology, and receptor relationship remain unresolved in later review literature.
- Catalog identity, purity, sequence, sterility, and stability require batch-specific documentation.
- No dosage, administration, treatment, or self-experimentation guidance is provided.
Regulatory and identity note
Investigational research peptide; not presented as an approved therapeutic. The FDA GSRS record for emideltide is an identity record and does not itself establish approval.
Use DSIP as the catalog display name and keep Delta Sleep-Inducing Peptide and Emideltide as traceable aliases. Do not treat DSIP, phosphorylated DSIP, and DSIP-like analogues as interchangeable without analytical evidence.